Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F22%3A10435353" target="_blank" >RIV/00216208:11110/22:10435353 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/22:10435353 RIV/00064211:_____/22:S0000013
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Bs7GlnzJuv" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Bs7GlnzJuv</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/dth.15277" target="_blank" >10.1111/dth.15277</a>

Result language
angličtina
Original language name
Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities
Original language description
The management of psoriasis in HIV-positive patients is challenging, particularly as data onbiologic therapy safety and efficacy in HIV-positive patients are limited. Risankizumab is a humanized IgG1 monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23) approved to treat psoriasis. Risankizumab was generally well tolerated in clinical trials and found to be relatively safe. Thus, it could be a suitable treatment for patients with chronic infections such as HIV.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)